Michelle Brennan, David DeBruin, Chinye Nwokolo, Katey S. Hunt, Alexander Piening, Maureen J. Donlin, Stephen T. Ferris, Ryan M. Teague, Richard J. DiPaolo, Elise Alspach
{"title":"T-cell expression of CXCL13 is associated with immunotherapy response in a sex-dependent manner in patients with lung cancer","authors":"Michelle Brennan, David DeBruin, Chinye Nwokolo, Katey S. Hunt, Alexander Piening, Maureen J. Donlin, Stephen T. Ferris, Ryan M. Teague, Richard J. DiPaolo, Elise Alspach","doi":"10.1158/2326-6066.cir-23-0826","DOIUrl":null,"url":null,"abstract":"Emerging evidence in preclinical models demonstrates that antitumor immunity is not equivalent between males and females. However, more investigation in patients and across a wider range of cancer types is needed to fully understand sex as a variable in tumor immune responses. We investigated differences in T-cell responses between male and female patients with lung cancer by performing sex-based analysis of single cell transcriptomic datasets. We found that the transcript encoding CXC motif chemokine ligand 13 (CXCL13), which has recently been shown to correlate with T-cell tumor specificity, is expressed at greater levels in T cells isolated from female compared to male patients. Furthermore, increased expression of CXCL13 was associated with response to PD-1–targeting immunotherapy in female but not male patients. These findings suggest that there are sex-based differences in T-cell function required for response to anti–PD-1 therapy in lung cancer that may need to be considered during patient treatment decisions.","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":"84 1","pages":""},"PeriodicalIF":8.1000,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2326-6066.cir-23-0826","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Emerging evidence in preclinical models demonstrates that antitumor immunity is not equivalent between males and females. However, more investigation in patients and across a wider range of cancer types is needed to fully understand sex as a variable in tumor immune responses. We investigated differences in T-cell responses between male and female patients with lung cancer by performing sex-based analysis of single cell transcriptomic datasets. We found that the transcript encoding CXC motif chemokine ligand 13 (CXCL13), which has recently been shown to correlate with T-cell tumor specificity, is expressed at greater levels in T cells isolated from female compared to male patients. Furthermore, increased expression of CXCL13 was associated with response to PD-1–targeting immunotherapy in female but not male patients. These findings suggest that there are sex-based differences in T-cell function required for response to anti–PD-1 therapy in lung cancer that may need to be considered during patient treatment decisions.
临床前模型的新证据表明,男性和女性的抗肿瘤免疫力并不相同。然而,要充分了解性别作为肿瘤免疫反应中的一个变量,还需要对患者和更广泛的癌症类型进行更多的调查。我们通过对单细胞转录组数据集进行基于性别的分析,研究了肺癌男女患者之间 T 细胞反应的差异。我们发现,与男性患者相比,编码 CXC motif 趋化因子配体 13(CXCL13)的转录本在女性患者分离出的 T 细胞中的表达水平更高。此外,CXCL13表达的增加与女性患者而非男性患者对PD-1靶向免疫疗法的反应有关。这些研究结果表明,肺癌患者对抗PD-1疗法产生反应所需的T细胞功能存在性别差异,患者在做出治疗决定时可能需要考虑到这一点。
期刊介绍:
Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes.
Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.